127 related articles for article (PubMed ID: 22243363)
1. The relationship of electrocardiographic left ventricular hypertrophy to decreased serum potassium.
Okin PM; Kjeldsen SE; Lindholm LH; Dahlöf B; Devereux RB
Blood Press; 2012 Jun; 21(3):146-52. PubMed ID: 22243363
[TBL] [Abstract][Full Text] [Related]
2. Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
Okin PM; Hille DA; Kjeldsen SE; Lindholm LH; Edelman JM; Dahlöf B; Devereux RB
Am J Hypertens; 2010 Jul; 23(7):786-93. PubMed ID: 20395941
[TBL] [Abstract][Full Text] [Related]
3. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Wedel H; Lindholm LH; Dahlöf B;
JAMA; 2004 Nov; 292(19):2343-9. PubMed ID: 15547161
[TBL] [Abstract][Full Text] [Related]
4. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
[TBL] [Abstract][Full Text] [Related]
5. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
Okin PM; Wachtell K; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Julius S; Lindholm LH; Nieminen MS; Edelman JM; Hille DA; Dahlöf B
JAMA; 2006 Sep; 296(10):1242-8. PubMed ID: 16968848
[TBL] [Abstract][Full Text] [Related]
6. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Dahlöf B;
Ann Intern Med; 2007 Sep; 147(5):311-9. PubMed ID: 17785486
[TBL] [Abstract][Full Text] [Related]
7. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
Okin PM
J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
[TBL] [Abstract][Full Text] [Related]
8. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
Oikarinen L; Nieminen MS; Toivonen L; Viitasalo M; Wachtell K; Papademetriou V; Jern S; Dahlöf B; Devereux RB; Okin PM;
Am Heart J; 2003 May; 145(5):919-25. PubMed ID: 12766755
[TBL] [Abstract][Full Text] [Related]
9. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.
Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Lindholm LH; Dahlöf B;
Hypertension; 2007 Nov; 50(5):984-90. PubMed ID: 17893425
[TBL] [Abstract][Full Text] [Related]
10. Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.
Okin PM; Wachtell K; Gerdts E; Dahlöf B; Devereux RB
J Hypertens; 2014 Dec; 32(12):2472-8; discussion 2478. PubMed ID: 25340854
[TBL] [Abstract][Full Text] [Related]
11. Persistence of left ventricular hypertrophy is associated with increased cardiovascular morbidity and mortality in hypertensive patients with lower achieved systolic pressure during antihypertensive treatment.
Okin PM; Hille DA; Kjeldsen SE; Dahlöf B; Devereux RB
Blood Press; 2014 Apr; 23(2):71-80. PubMed ID: 23721506
[TBL] [Abstract][Full Text] [Related]
12. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
Bang CN; Devereux RB; Okin PM
J Electrocardiol; 2014; 47(5):630-5. PubMed ID: 25052475
[TBL] [Abstract][Full Text] [Related]
13. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Dahlöf B
Hypertension; 2000 Nov; 36(5):766-73. PubMed ID: 11082141
[TBL] [Abstract][Full Text] [Related]
14. Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study.
Larstorp AC; Okin PM; Devereux RB; Olsen MH; Ibsen H; Dahlöf B; Kjeldsen SE; Wachtell K
Am J Hypertens; 2012 Oct; 25(10):1101-9. PubMed ID: 22717544
[TBL] [Abstract][Full Text] [Related]
15. Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension.
Okin PM; Hille DA; Kjeldsen SE; Devereux RB
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29151037
[TBL] [Abstract][Full Text] [Related]
16. Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study.
Okin PM; Devereux RB; Liu JE; Oikarinen L; Jern S; Kjeldsen SE; Julius S; Wachtell K; Nieminen MS; Dahlöf B
J Hum Hypertens; 2004 Jun; 18(6):403-9. PubMed ID: 15057252
[TBL] [Abstract][Full Text] [Related]
17. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
[TBL] [Abstract][Full Text] [Related]
18. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
Larstorp AC; Okin PM; Devereux RB; Olsen MH; Ibsen H; Dahlöf B; Kjeldsen SE; Wachtell K
J Hum Hypertens; 2011 Mar; 25(3):178-85. PubMed ID: 20505749
[TBL] [Abstract][Full Text] [Related]
19. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
Dahlof B; Zanchetti A; Diez J; Nicholls MG; Yu CM; Barrios V; Aurup P; Smith RD; Johansson M;
J Hypertens; 2002 Sep; 20(9):1855-64. PubMed ID: 12195129
[TBL] [Abstract][Full Text] [Related]
20. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
Okin PM; Devereux RB; Nieminen MS; Jern S; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Dahlöf B;
Circulation; 2006 Jan; 113(1):67-73. PubMed ID: 16365195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
